Disease Modifying Drugs Targeting β-amyloid

Overview

Journal Am J Alzheimers Dis Other Demen

Publisher Sage Publications

Specialty Neurology

Date 2012 Jul 21

PMID 22815077

Citations 20

Authors

S N Ozudogru

C F Lippa

Affiliations

Soon will be listed here.

Abstract

At this time there are no effective methods to alter the disease course in Alzheimer's disease. All FDA approved interventions are for symptomatic relief only. However, it is an exciting time as many agents in development have theorhetical potential to impact the disease course. This review discusses some of the agents that have been in clinical trials, particularly those that affect amyloid processing. Some agents have failed while others still provide hope. Since amyloid is the peptide most closely linked to disease pathogenesis, it is possible that some of the anti-amyloid agents will impact the disease progression in a meaningful way.

Citing Articles

Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History.

Bermejo-Pareja F, Del Ser T J Clin Med. 2024; 13(2).

PMID: 38256670 PMC: 10816332. DOI: 10.3390/jcm13020536.

Attempts to Develop Vaccines Against Alzheimer's Disease: A Systematic Review of Ongoing and Completed Vaccination Trials in Humans.

Thakur A, Bogati S, Pandey S Cureus. 2023; 15(6):e40138.

PMID: 37425610 PMC: 10329479. DOI: 10.7759/cureus.40138.

Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia.

Decourt B, Noorda K, Noorda K, Shi J, Sabbagh M J Exp Pharmacol. 2022; 14:331-352.

PMID: 36339394 PMC: 9632331. DOI: 10.2147/JEP.S265626.

Extracellular Vesicles as a Neprilysin Delivery System Memory Improvement in Alzheimer's Disease.

Izadpanah M, Dargahi L, Ai J, Asgari Taei A, Barough S, Mowla S Iran J Pharm Res. 2020; 19(2):45-60.

PMID: 33224210 PMC: 7667544. DOI: 10.22037/ijpr.2020.112062.13508.

Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.

Behl T, Kaur I, Fratila O, Brata R, Bungau S Int J Mol Sci. 2020; 21(20).

PMID: 33050199 PMC: 7589257. DOI: 10.3390/ijms21207443.

References

Imbimbo B, Giardina G . γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem. 2011; 11(12):1555-70. DOI: 10.2174/156802611795860942. View

Vlad S, Miller D, Kowall N, Felson D . Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008; 70(19):1672-7. PMC: 2758242. DOI: 10.1212/01.wnl.0000311269.57716.63. View

Tamboli I, Barth E, Christian L, Siepmann M, Kumar S, Singh S . Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. J Biol Chem. 2010; 285(48):37405-14. PMC: 2988346. DOI: 10.1074/jbc.M110.149468. View

Peter C, Hongwan D, Kupfer A, Lauterburg B . Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000; 56(3):247-50. DOI: 10.1007/s002280000124. View

Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M . A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010; 30(33):11157-66. PMC: 6633483. DOI: 10.1523/JNEUROSCI.2884-10.2010. View

Steen E, Terry B, Rivera E, Cannon J, Neely T, Tavares R . Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?. J Alzheimers Dis. 2005; 7(1):63-80. DOI: 10.3233/jad-2005-7107. View

Orgogozo J, Gilman S, Dartigues J, Laurent B, Puel M, Kirby L . Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003; 61(1):46-54. DOI: 10.1212/01.wnl.0000073623.84147.a8. View

Salloway S, Sperling R, Gilman S, Fox N, Blennow K, Raskind M . A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009; 73(24):2061-70. PMC: 2790221. DOI: 10.1212/WNL.0b013e3181c67808. View

Black R, Sperling R, Safirstein B, Motter R, Pallay A, Nichols A . A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010; 24(2):198-203. PMC: 3715117. DOI: 10.1097/WAD.0b013e3181c53b00. View

10.

Luo X, Yan R . Inhibition of BACE1 for therapeutic use in Alzheimer's disease. Int J Clin Exp Pathol. 2010; 3(6):618-28. PMC: 2907124. View

11.

McLaurin J, Cecal R, Kierstead M, Tian X, Phinney A, Manea M . Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med. 2002; 8(11):1263-9. DOI: 10.1038/nm790. View

12.

Evin G, Barakat A, Masters C . BACE: Therapeutic target and potential biomarker for Alzheimer's disease. Int J Biochem Cell Biol. 2010; 42(12):1923-6. DOI: 10.1016/j.biocel.2010.08.017. View

13.

Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith S . Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol. 2005; 58(3):430-5. DOI: 10.1002/ana.20592. View

14.

Perry T, Lahiri D, Sambamurti K, Chen D, Mattson M, Egan J . Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res. 2003; 72(5):603-12. DOI: 10.1002/jnr.10611. View

15.

Medina D, Caccamo A, Oddo S . Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2010; 21(2):140-9. PMC: 2992595. DOI: 10.1111/j.1750-3639.2010.00430.x. View

16.

Ma L, Yang Z, Li C, Zhu Z, Shen X, Hu L . Design, synthesis and SAR study of hydroxychalcone inhibitors of human β-secretase (BACE1). J Enzyme Inhib Med Chem. 2011; 26(5):643-8. DOI: 10.3109/14756366.2010.543420. View

17.

Pettersson M, Kauffman G, Am Ende C, Patel N, Stiff C, Tran T . Novel γ-secretase modulators: a review of patents from 2008 to 2010. Expert Opin Ther Pat. 2011; 21(2):205-26. DOI: 10.1517/13543776.2011.547479. View

18.

Ghosh A, Gemma S, Tang J . beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics. 2008; 5(3):399-408. PMC: 2963069. DOI: 10.1016/j.nurt.2008.05.007. View

19.

Feldman H, Doody R, Kivipelto M, Sparks D, Waters D, Jones R . Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010; 74(12):956-64. DOI: 10.1212/WNL.0b013e3181d6476a. View

20.

Petersen R, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E . Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56(3):303-8. DOI: 10.1001/archneur.56.3.303. View